SEC Form 4 · accession 0001209191-17-059138
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Biller
Officer — Chief Scientific Officer
Period of report
Nov 1, 2017
Accepted (ET)
Nov 3, 2017 · 4:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock | Nov 1, 2017 | M | 2,146 | $31.64 | A | 8,410 | D | |
| Common stock | Nov 1, 2017 | S | 100 | $65.45 | D | 8,310 | D | |
| Common stockF3 | Nov 1, 2017 | S | 200 | $63.62 | D | 8,110 | D | |
| Common stockF4 | Nov 1, 2017 | S | 900 | $63.09 | D | 7,210 | D | |
| Common stockF5 | Nov 1, 2017 | S | 946 | $61.81 | D | 6,264 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F6 | $31.64 | Nov 1, 2017 | M | 2,146 | D | — | Mar 4, 2024 | Common stock | 2,146 | 32,185 | D |
Explanation of responses
- F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F3The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $63.60 to $63.63. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $62.57 to $63.49. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $61.36 to $62.34. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F6This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.